Namenda: profile and news

Forest Laboratories Receives Patent Term Extension for Lexapro Mar 4, 2006
...hypertension. Namenda is the first approved therapy in the United States for those with moderate to severe Alzheimer's disease. - ag-IP-news Agency,

Alzheimer’s Disease Questions and Answers Feb 28, 2006
Namenda (memantine) is the first drug approved for the treatment of moderate to severe AD. Namenda is an NMDA receptor antagonist ... - KPHO Phoenix,

Eisai Eyes Alzheimer's Market Feb 15, 2006
Approval from the FDA would allow the pharmaceutical to move in on the turf currently occupied by Forest Labs(NYSE: FRX), which markets Namenda, the only FDA ... - MSNBC

Improving Alzheimer’s treatment Feb 6, 2006
...said, “a new class of medications, called NMDA receptor antagonists, has been developed – represented by a drug called memantine and marketed as Namenda. ... - San Bernardino Sun,

Update on major health topics Feb 19, 2006
THIS STUDY involved 175 people with moderate to severe Alzheimer's disease who had been randomly assigned in an earlier study to take memantine (Namenda) or a ... - Seattle Times,

Replidyne and Forest Laboratories Announce FDA Acceptance for ... Feb 23, 2006
...indicated for the initial and maintenance treatment of major depressive disorder and for generalized anxiety disorder in adults; Namenda(R) (memantine HCl), an ... - Finanzen.net,

Evotec completes Phase I component for Alzheimer’s drug Feb 8, 2006
...the expiry of their patents and the launch of new and combination products, such as the NMDA receptor antagonist recently launched by Forest's Namenda, and the ... - In-PharmaTechnologist.com,

What Is Alzheimer’s Disease? Feb 17, 2006
The side effects for the most commonly used medications: Aricept, Cognex, Exelon and Namenda can include nausea and vomiting, liver damage, psychiatric ... - DailyIndia.com,

Alzheimer's Drugs Offer Modest Improvements, Equal Effectiveness Feb 5, 2006
10, 2006 - Memantine, marketed as Namenda, was approved in 2003 as the first drug okayed by the FDA for the treatment of moderate to severe Alzheimer's disease ... - SeniorJournal.com,

Neurobiological Technologies Reports Fiscal 2006 Second Quarter ... Feb 9, 2006
...to support three phase III trials for XERECEPT, on behalf of Celtic Pharma, while receiving royalty revenue from the product, Namenda, for Alzheimer's disease. ... - PR Newswire (press release),

Neurobiological Technologies Reports Fiscal 2006 Second Quarter ... 09 Feb 2006
...to support three phase III trials for XERECEPT, on behalf of Celtic Pharma, while receiving royalty revenue from the product, Namenda, for Alzheimer's disease. ... - PR Newswire (press release),

Namenda® Slows Severe Alzheimer's Symptoms For One Year, Follow ... Jan 10, 2006
...to the results of a new multicenter study that provides additional support for the continuing effectiveness of the treatment, called Namenda®, for patients in ... - Medical News Today (press release),

Memantine (Namenda) Found Effective for Advanced Alzheimer's ... Jan 10, 2006
10, 2006 - Memantine, marketed as Namenda, was approved in 2003 as the first drug okayed by the FDA for the treatment of moderate to severe Alzheimer's disease ... - SeniorJournal.com,

Drug Slows Alzheimer's Disease Jan 9, 2006
Jan. 9, 2006 -- The drug Namenda slows Alzheimer's disease for at least a year, doctors report in the Archives of Neurology. Namenda ... - WebMD

Drug slows down Alzheimer's Jan 10, 2006
The discovery involving the drug memantine (Namenda) builds on previous research that found the medication benefited Alzheimer's patients for up to six months. ... - Health24.com,

Dementia patients have more treatment options available Jan 31, 2006
...at least temporarily. A fourth medication, Namenda, has similar benefits by a somewhat different mechanism in the brain. So it can ... - Newstarget.com,

Drug slows Alzheimer's in long term Feb 1, 2006
THIS STUDY involved 175 people with moderate to severe Alzheimer's disease who had been randomly assigned in an earlier study to take memantine (Namenda) or a ... - NorthJersey.com,

UPDATE 3-Forest Labs quarterly profit falls 25 percent Jan 17, 2006
New York-based Forest is betting on newer drugs, high blood pressure drug Benicar and Alzheimer's treatment Namenda, to offset the drop in antidepressant sales ... - Reuters

Quick Study: Alzheimer's Jan 29, 2006
THIS STUDY involved 175 people with moderate to severe Alzheimer's disease who had been randomly assigned in an earlier study to take memantine (Namenda) or a ... - Evansville Courier & Press (subscription),

Drug Slows Alzheimer's Progression Jan 9, 2006
The discovery involving the drug memantine (Namenda) builds on previous research that found the medication benefited Alzheimer's patients for up to six months. ... - HealthCentral.com

Findings Indicate Continuing Benefits Over 1 Year in Subjects ... Jan 11, 2006
NEW YORK, NY -- January 11, 2006 -- Namenda (memantine), which has yielded success in treating patients with moderate to advanced cases of Alzheimer's disease ... - DG News

Forest Looks for a Spark Jan 16, 2006
Attempts to secure government approval for expanded uses of Lexapro and Namenda, an Alzheimer's treatment, have been rebuffed. Namenda ... - TheStreet.com

Forest Labs 3Q profit tumbles 25 percent Jan 17, 2006
...and Ivax Corp., which are planning to combine operations, were each challenging the patent. Sales of Alzheimer's drug Namenda rose 23 percent to $124 million. ... - BusinessWeek

Forest Laboratories, Inc. Reports Q3'06 Diluted Earnings Per Share ... Jan 17, 2006
Sales of Namenda(R), an NMDA receptor antagonist for the treatment of moderate to severe Alzheimer's disease, totaled $124,022,000 in the quarter compared to ... - Biotech Intelligence (press release),

Forest Labs: Is Different Better? Jan 17, 2006
But Namenda, a drug for the treatment of Alzheimer's disease, continued to be something of a bright spot, with sales growing more than 23%. ... - Motley Fool

Will Acquisitions Patch Merck's Pipeline? Jan 26, 2006
...end up competing with the best-selling Aricept, co-marketed by Pfizer (NYSE: PFE) and Eisai (OTC BB: ESALY.PK), as well as Forest Labs' (NYSE: FRX) Namenda. ... - Motley Fool

New causes, treatments for Alzheimer's Jan 27, 2006
I have also begun prescribing a newer medication called Namenda, which has been approved by the US Federal Drug Administration to treat moderate to severe ... - Contra Costa Times,

Forest's Quarterly Profit Falls on Antidepressant Competition Jan 17, 2006
...and for the Namenda Alzheimer's disease medicine from Germany's Merz & Co. (Forest will hold a conference call at 10 am New York time through its Web site. ... - Bloomberg

Mylan Laboratories and Forest Laboratories Announce Nebivolol ... Jan 12, 2006
...indicated for the initial and maintenance treatment of major depressive disorder and for generalized anxiety disorder in adults; Namenda(R) (memantine HCl), an ... - PharmaLive.com (press release),

Study: Alzheimer's drug safe, effective Jan 9, 2006
...editorial to the study. Memantine HCl is made by Forest Laboratories Inc. and is marketed under the name Namenda. It was the first ... - myDNA.com,

Dr. Barry Reisberg and Associates Conclude One Year Study on ... Jan 10, 2006
...used as a pivotal trial in memantine's approval first in the EU in 2002, and subsequently in the US in 2003 and, subsequently, went on the US market as Namenda ... - PR Newswire (press release),

Forest Labs quarterly profit falls short again Jan 17, 2006
Sales of Forest’s Alzheimer’s disease treatment Namenda grew 23%. Shares of Forest Labs slumped more than 10% during premarket trading, to $39.52. ... - Crain's New York Business,

AstraZeneca Is The Latest To Join Alzheimer's Fight Jan 6, 2006
Four name-brand drugs are in common use for Alzheimer's: Pfizer's (PFE) Aricept, Novartis' (NVS) Exelon, Ortho-McNeil's Razadyne and Forest Labs' (FRX) Namenda ... - Investor's Business Daily (subscription)

Alzheimer's Treatments Reviewed by NeuroInvestment Dec 5, 2005
The current armamentarium of cholinesterase inhibitors and Namenda, even when given in combination, provides only modest, time-limited benefit to a minority of ... - Market Wire (press release)

Disease made him a statistic – and a hero Dec 8, 2005
But drugs such as Aricept and Namenda may help delay symptoms when the disease is diagnosed early.Experts say the most promising research suggests lifestyle ... - The State,

Gedeon Richter and Forest Laboratories Expand Relationship with ... Nov 28, 2005
...indicated for the initial and maintenance treatment of major depressive disorder and for generalized anxiety disorder in adults; Namenda® (memantine HCl), an N ... - Yahoo! News (press release)

STOPPING MEDICINE WITHOUT TELLING THE DOCTOR IS DANGEROUS Nov 30, 2005
...the progression of the illness. Namenda is another Alzheimer's medicine, and it works in a different way. It protects memory cells ... - Charlotte Sun-Herald,

The Fisher Center for Alzheimer's Research Foundation Celebrates ... Dec 2, 2005
...as Dr. William Netzer, Associate Researcher at the Fisher Center for Alzheimer's Disease Research, and Dr. Barry Reisberg, author of the "Namenda study" and ... - PR Newswire (press release),

Myriad's Flurizan shows promise in phase 2 Nov 15, 2005
Pfizer's/Eisai's Aricept led the pack in sales in 2004, followed by Forest Laboratories' Namenda, Johnson & Johnson's Reminyl, Novartis' Exelon and First ... - Science Daily (press release)

Healthbeat:Gene Therapy for Alzheimer's Nov 15, 2005
...early stage disease. For patients with moderate to more severe disease, the drug, Namenda®, may be helpful. At Rush University ... - WHOI,

Corcept Closes Enrollment of Proof of Concept Clinical Study ... Sep 26, 2005
The study protocol prohibited the concomitant use of Namenda (memantine), a recently approved treatment for Alzheimer's disease which was commercialized after ... - PR Newswire (press release),

Corcept studies hurt by slow enrollment Sep 26, 2005
Corcept said it was difficult to find more patients for the Alzheimer's study because the trial protocol prohibits the use of Namenda, a recently approved ... - BusinessWeek

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce ... Sep 28, 2005
...indicated for the initial and maintenance treatment of major depressive disorder and for generalized anxiety disorder in adults; Namenda®(memantine HCl), an N ... - Yahoo! News (press release)

NTI Sells Xerecept Rights To Celtic Pharma For $48M Sep 20, 2005
Aside from developing Xerecept and Viprinex, NTI receives revenues from its one marketed product - Namenda (memantine HCL), which received FDA approval in ... - BioWorld Online (subscription),

John La Porte/Fort Morgan Times Sep 9, 2005
Bob has participated in Alzheimer's research; he takes several medications -- Aricept, Namenda and a new powder that is in the trial stage. ... - Fort Morgan Times,

John La Porte/Fort Morgan Times 09 Sep 2005
Bob has participated in Alzheimer's research; he takes several medications -- Aricept, Namenda and a new powder that is in the trial stage. ... - Fort Morgan Times,

FDA Approvals: Aceon, 0.1% Alphagan P, Namenda Oral Solution Aug 25, 2005
18, memantine HCl 2 mg/mL oral solution (Namenda, marketed by Forest Laboratories, Inc., under license from Merz Pharma GmbH & Co.) was launched in the US ... - Medscape (subscription)

Oral Solution Formulation of Namenda(R), the Only FDA-Approved ... Aug 18, 2005
NEW YORK, Aug. 18 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) announced today that an oral solution formulation of Namenda(R)(memantine HCl ... - PR Newswire (press release),

Oral Solution Formulation of Namenda(R), the Only FDA-Approved ... Aug 18, 2005
...announced today that an oral solution formulation of Namenda(R)(memantine HCl), the only FDA-approved treatment for moderate to severe Alzheimer's disease, is ... - Finanzen.net,

Namenda Alzheimer’s Medication Now Available in Liquid Aug 19, 2005
19, 2005 – The only drug approved by the Food and Drug Administration for the treatment of moderate-to-severe Alzheimer’s disease – Namenda (memantine HCl ... - SeniorJournal.com,

Oral Solution Formulation of Namenda(R), the Only FDA-Approved ... Aug 18, 2005
18 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX - News) announced today that an oral solution formulation of Namenda®(memantine HCl), the ... - Yahoo News (press release)

Eisai: Aricept in for severe approval Sep 2, 2005
An approval in this indication would not only lift sales but, with Forest having received a non-approvable letter for Namenda in mild to moderate AD in July ... - Pharmaceutical Business Review

An Opportunity Not to Forget Sep 2, 2005
...well. Today, Forest Labs' (NYSE: FRX) Namenda is the only FDA-approved treatment for moderate-to-severe Alzheimer's symptoms. Its ... - Motley Fool

New Alzheimer's Drug Approved By FDA Aug 20, 2005
Oral solution offers an alternative that may make the ingestion of Namenda easier for those patients who have trouble swallowing tablets. ... - All Headline News

S&P 500 Scorecard: Gateway, Deere, Gap, Limited Lead Index Down Aug 19, 2005
...revenue from antidepressants, said an oral (FRX, $42.68) solution of Namenda, the only FDA-approved treatment for moderate to severe Alzheimer's disease, is ... - Bloomberg

Stock Scorecard Aug 21, 2005
LABORATORIES INC., up 6.5 percent to $42.68: The drugmaker, which gets most of its revenue from antidepressants, said an oral solution of Namenda, the only FDA ... - Asbury Park Press,